# US 10,765,720 B2 · Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,720 B2
- Document ID: US10765720B2
- Status: Granted
- Kind: B2
- Application number: 16/207,441
- Filed: 2018-12-03
- Published: 2019-06-27
- Granted: 2020-09-08
- Earliest claimed: 2017-12-04
- Assignees: Samsung Life Public Welfare Foundation; Pusan National University Industry-University Cooperation Foundation
- Applicants: Samsung Life Public Welfare Foundation; Pusan National University Industry-University Cooperation Foundation
- Inventors: Yun Sil Chang; Won Soon Park; So Yoon Ahn; Dong Kyung Sung; Young Eun Kim; Jae Ho Kim
- Web page: https://patentgrep.com/patent/US10765720B2

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.

## Claims

### Claim 1

A method of treating hyperoxia-induced lung injury comprising:
administering to a subject in need thereof an effective amount of a WKYMVm peptide, the WKYMVm peptide comprising the sequence of SEQ ID NO: 1,
wherein the hypoxia-induced lung injury is bronchopulmonary dysplasia, and
wherein the effective amount of the WKYMVm is from 1-100 μM.

### Claim 2 (depends on 1)

The method of claim 1, wherein the WKYMVm peptide activates formyl-peptide receptor type 2 (FPR2).

### Claim 3 (depends on 1)

The method of claim 1, wherein the WKYMVm peptide increases the phosphorylation of an extracellular signal-regulated kinase (ERK).

### Claim 4 (depends on 1)

The method of claim 1, wherein the WKYMVm peptide induces angiogenesis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the WKYMVm peptide reduces inflammation.

### Claim 6

A method of alleviating hyperoxia-induced lung injury comprising:
administering to a subject in need thereof an effective amount of a WKYMVm peptide to an individual, the WKYMVm peptide comprising the sequence of SEQ ID NO: 1,
wherein the hypoxia-induced lung injury is bronchopulmonary dysplasia, and
wherein the effective amount of the WKYMVm is from 1-100 μM.

### Claim 7 (depends on 6)

The method of claim 6, wherein the WKYMVm peptide activates formyl-peptide receptor type 2 (FPR2).

### Claim 8 (depends on 6)

The method of claim 6, wherein the WKYMVm peptide increases the phosphorylation of an extracellular signal-regulated kinase (ERK).

### Claim 9 (depends on 6)

The method of claim 6, wherein the WKYMVm peptide induces angiogenesis.

### Claim 10 (depends on 6)

The method of claim 6, wherein the WKYMVm peptide reduces inflammation.